Navigation Links
Replidyne Announces 2007 Fourth Quarter and Full Year Results
Date:2/26/2008

007 was $58.6 million. Upon termination of the commercialization and development agreement with Forest, all unamortized upfront and milestone payments as well as contract revenue for funded activities were fully recognized as revenue in the period ended May 7, 2007. Replidyne will not report any revenue under this agreement for future reporting periods.

Research and development expenses in the fourth quarter of 2007 were $14.9 million compared to $13 million in the corresponding quarter of 2006. Faropenem related expense represented approximately 77% of total research and development expense in the quarter, primarily for costs to prepare for patient enrollment in three planned Phase III clinical trials of faropenem, one for treatment of acute bacterial sinusitis and two for treatment of community acquired pneumonia, as well as costs to support the ongoing placebo-controlled Phase III clinical trial of faropenem for treatment of acute exacerbation of chronic bronchitis. Fourth quarter 2007 expense also included $1.7 million related to contingent supply agreement costs related to the delayed development program for faropenem. Additionally, research and development expense included increased costs for preclinical activities targeted to Replidyne's discovery research programs, primarily its C. difficile and inhibition of DNA replication programs offset by decreased expense related to the REP8839 program that was suspended in December 2007. Research and development expense was $43.3 million for the full year 2007 compared to $38.3 million in 2006. The increase in full year research and development expense reflected increased costs to prepare for future clinical trials of faropenem and ongoing execution of the placebo-controlled Phase III clinical trial for treatment of acute exacerbations of chronic bronchitis as well as increased preclinical activities within the C. difficile and inhibition of DNA replication programs. These increases were partially offset by low
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014  U.S. ... portfolio by signing an exclusive license for technology developed ... to control gene expression in plants, including for applications ... species. The technology was developed under ... science officer at Kultevat and former president of the ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Sigma the Greeks would be proud , ,So ... better question might be, how many projects can you juggle at ... plate? Are they the ones that will best improve your organizations ... be for you! , ,6 Sigma (6σ) is a program ...
... implementation advice offered , ,Waukesha, Wis. Whenever a ... it seldom begins its life as an instant success. More ... contraption that is waiting for early adopters, who are often ... studied by those experienced in the field, tested in real-world ...
... Quintessence Biosciences, Inc. has formed a scientific advisory ... cancer therapeutics. , ,Announced last week by President ... board will consist of distinguished scientific leaders who will ... Biosciences, Inc. They will also assist the company as ...
Cached Biology Technology:Part 6 Project Performance Get on the path to continuous improvement 2Part 6 Project Performance Get on the path to continuous improvement 3Part 6 Project Performance Get on the path to continuous improvement 4Laying the foundation for RFID 2Laying the foundation for RFID 3Laying the foundation for RFID 4Quintessence Biosciences forms cancer therapeutic advisory board 2
(Date:9/19/2014)... biology professor will study the unique bioelectric signaling system ... benefit people,s health. The OU researcher is working ... to produce the signals used to map the world ... a rate of 500-600 discharges a second throughout their ... fish are extreme, but necessary for survival. , "There ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... Conn. , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... biometric authentication company focused on the growing m-commerce market, updates the ... world champion in the lightweight and light middleweight weight classes, ... Yesterday it was announced that Game of Thrones actor ... Married with Children star Katey Sagal have ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... impressive ceremony on May 14, Nobel Prize laureate Prof. ... innovator Prof. Michael S. Waterman of the University of ... University Honorary Doctorate degrees awarded at this year,s TAU ... community of previous honorees that includes heads of state, ...
... in Spanish . , WASHINGTON - Total losses ... all causes for the 2010/2011 winter, according to the annual ... the Apiary Inspectors of America (AIA). This is roughly ... the four previous years: 34 percent for the 2009/2010 winter, ...
... have replicated the inflammatory gene changes of a human ... nephropathy, using a mouse model developed by a UofL ... journal Experimental Nephrology . Diabetic nephropathy is the ... published an article that showed that our diabetic mouse ...
Cached Biology News:Tel Aviv University confers its highest honor on 8 distinguished individuals 2USDA/AIA survey reports 2010/2011 winter honey bee losses 2UofL researchers replicate human kidney gene changes in mouse model 2
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
The Protein Kinase Factsbooks (2 Volume Set)...
... Walker (1996) • This book offers ... studying proteins and peptides. Each tried ... instruction, timesaving troubleshooting tips, alternative procedures, ... reagents and suppliers. Topics covered range ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Biology Products: